HC Wainwright Issues Positive Outlook for INKT Earnings

Key Points

• HC Wainwright raised MiNK's Q1 2026 EPS estimate slightly (from -$0.78 to -$0.77), reaffirmed a Buy rating and a $35 price target, and models a long‑term turn to profitability (FY2030 EPS $1.31) despite near‑term losses.
• MiNK reported Q1 EPS of -$0.54, beating the consensus of -$0.68, while shares trade around $10.69 with a market cap of about $53M — implying significant upside to the $35 target but reflecting small‑cap, loss‑making risk.
• MiNK's agenT‑797 abstracts were accepted for presentation at ASGCT and ATS in May, potentially boosting scientific visibility, and DRW Securities initiated a new ~25,677‑share stake, bringing institutional ownership to roughly 2.87%.

MiNK Therapeutics, Inc. (NASDAQ:INKT - Free Report) - Equities researchers at HC Wainwright increased their Q1 2026 earnings per share estimates for shares of MiNK Therapeutics in a note issued to investors on Wednesday, April 1st. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.77) per share for the quarter, up from their previous forecast of ($0.78). HC Wainwright has a "Buy" rating and a $35.00 price target on the stock. The consensus estimate for MiNK Therapeutics' current full-year earnings is ($2.75) per share. HC Wainwright also issued estimates for MiNK Therapeutics' Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.91) EPS, Q4 2026 earnings at ($0.95) EPS, FY2026 earnings at ($3.50) EPS, FY2027 earnings at ($3.58) EPS, FY2028 earnings at ($1.27) EPS and FY2029 earnings at ($0.12) EPS.

Separately, Wall Street Zen upgraded shares of MiNK Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, January 19th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, MiNK Therapeutics presently has a consensus rating of "Hold" and a consensus target price of $35.00.

MiNK Therapeutics Stock Performance

Shares of INKT stock opened at $10.69 on Friday. MiNK Therapeutics has a fifty-two week low of $6.34 and a fifty-two week high of $76.00. The firm has a market capitalization of $53.13 million, a price-to-earnings ratio of -3.60 and a beta of 0.35. The stock's 50-day simple moving average is $10.88 and its 200-day simple moving average is $12.22.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.54) EPS for the quarter, beating analysts' consensus estimates of ($0.68) by $0.14.

Institutional Investors Weigh In On MiNK Therapeutics

An institutional investor recently bought a new position in MiNK Therapeutics stock. DRW Securities LLC bought a new stake in MiNK Therapeutics, Inc. (NASDAQ:INKT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 25,677 shares of the company's stock, valued at approximately $286,000. DRW Securities LLC owned about 0.55% of MiNK Therapeutics as of its most recent SEC filing. 2.87% of the stock is currently owned by institutional investors and hedge funds.

Key MiNK Therapeutics News

Here are the key news stories impacting MiNK Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and maintained a $35 price target (roughly 227% above the recent open), reinforcing broker support for INKT and providing a clear upside anchor for investors. Buy Rating Article
• Positive Sentiment: HC Wainwright raised several near‑term and FY estimates (Q1–Q3 2026, FY2026–FY2028), indicating the analyst now models smaller losses over the next few years — a constructive trend for valuation and investor sentiment even though the company remains loss-making.
• Positive Sentiment: MiNK’s agenT‑797 abstract was accepted for presentation at the ASGCT Annual Meeting (May) and an abstract accepted at the ATS conference (May), increasing scientific visibility and potential partnership/collaboration interest ahead of conference data releases. ASGCT Presentation Article ATS Presentation Article
• Neutral Sentiment: HC Wainwright published a long‑range view that includes a FY2030 EPS projection of $1.31 — a material turn to profitability in their model but distant and subject to development/execution risk.
• Negative Sentiment: HC Wainwright trimmed the Q4 2026 EPS forecast slightly (from ($0.92) to ($0.95)) and materially cut FY2029 from $0.49 to ($0.12), introducing uncertainty about the timing and durability of the path to positive earnings.
• Negative Sentiment: Insider selling and mixed hedge‑fund activity were noted in recent coverage (several insider sales reported), which can weigh on sentiment for a small‑cap biotech where insider moves are closely watched by the market. Quiver Article

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company's proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK's preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.